{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:42:55Z","timestamp":1783356175774,"version":"3.54.6"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The aim of this review is to elucidate the type and frequency of ocular adverse events associated with selinexor with a goal to quantify the occurrence of these events in our investigator-initiated trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively reviewed medical records of 174 patients treated with at least one dose of selinexor in combination with multiple standard chemotherapy or immunotherapy agents between July 2015 and July 2020 at a comprehensive cancer center in the U.S. All reported ocular adverse events were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 174 patient medical records were reviewed. All patients received at least one dose of selinexor in combination with multiple standard chemotherapy or immunotherapy agents in our cohort of patients with advanced malignancies. A total of 34 (19.54%) patients experienced 37 ocular adverse events. The most frequently reported ocular symptom was blurred vision, which was reported in 22 (12.64%) patients. The most frequently reported treatment-related adverse event was dry eye syndrome reported in 21 (12.1%) patients, and 19 (10.9%) of them were diagnosed with mild dry eye. The second most common treatment-related adverse event was the progression of age-related nuclear sclerosis (cataract) reported in 7 (4.0%) patients. None of the ocular adverse events required therapy discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our findings highlight that ocular adverse events associated with oral selinexor were mild. The most frequently reported ocular treatment-related adverse events were mild dry eye and progression of age-related nuclear sclerosis. None of the ocular adverse events required therapy discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Patients receiving selinexor in combination with multiple standard chemotherapy or immunotherapy agents were reviewed, with a total of 34 patients experiencing 37 ocular adverse events. Findings highlight that ocular adverse events associated with oral selinexor were mild. The most frequently reported ocular treatment-related adverse events were mild dry eye and progression of age-related nuclear sclerosis. None of the ocular adverse events required therapy discontinuation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13756","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T04:56:58Z","timestamp":1615957018000},"page":"619-623","source":"Crossref","is-referenced-by-count":11,"title":["Overview of Ocular Side Effects of Selinexor"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-0365","authenticated-orcid":false,"given":"Nagham","family":"Al-Zubidi","sequence":"first","affiliation":[{"name":"Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan S.","family":"Gombos","sequence":"additional","affiliation":[{"name":"Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi Rodon","family":"Ahnert","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Karp","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda Meric","family":"Bernstam","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-8513","authenticated-orcid":false,"given":"Aung","family":"Naing","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,8]]},"reference":[{"key":"2022020214131837100_onco13756-bib-0001","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","article-title":"Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma","volume":"36","author":"Vogl","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022020214131837100_onco13756-bib-0002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","article-title":"XPO1-dependent nuclear export as a target for cancer therapy","volume":"13","author":"Azizian","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2022020214131837100_onco13756-bib-0003","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","article-title":"Selinexor: First global approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"2022020214131837100_onco13756-bib-0004","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"7","author":"Gravina","year":"2014","journal-title":"J Hematol Oncol"},{"key":"2022020214131837100_onco13756-bib-0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40164-015-0002-5","article-title":"Selective inhibitors of nuclear export (SINE) in hematological malignancies","volume":"4","author":"Das","year":"2015","journal-title":"Exp Hematol Oncol"},{"key":"2022020214131837100_onco13756-bib-0006","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","article-title":"Selective inhibitors of nuclear export (SINE)\u2013a novel class of anti-cancer agents","volume":"7","author":"Parikh","year":"2014","journal-title":"J Hematol Oncol"},{"key":"2022020214131837100_onco13756-bib-0007","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-7-46","article-title":"XPO1\/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)","volume":"7","author":"Gravina","year":"2014","journal-title":"J Hematol Oncol"},{"key":"2022020214131837100_onco13756-bib-0008","doi-asserted-by":"crossref","first-page":"16581","DOI":"10.18632\/oncotarget.7667","article-title":"Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma","volume":"7","author":"Nakayama","year":"2016","journal-title":"Oncotarget"},{"key":"2022020214131837100_onco13756-bib-0009","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13058-017-0878-6","article-title":"Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer","volume":"19","author":"Arango","year":"2017","journal-title":"Breast Cancer Res"},{"key":"2022020214131837100_onco13756-bib-0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30686-1","article-title":"Anti-tumor efficacy of selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor","volume":"8","author":"Subhash","year":"2018","journal-title":"Sci Rep"},{"key":"2022020214131837100_onco13756-bib-0011","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/1078-0432.CCR-19-1728","article-title":"Preclinical assessment with clinical validation of selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma","volume":"26","author":"Azmi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2022020214131837100_onco13756-bib-0012","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1200\/JCO.2016.67.6346","article-title":"Phase Ib study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma","volume":"34","author":"Gounder","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022020214131837100_onco13756-bib-0013","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03","author":"National Cancer Institute","year":"2010"},{"key":"2022020214131837100_onco13756-bib-0014","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.ophtha.2012.03.002","article-title":"Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: Report of 5 cases","volume":"119","author":"Saint-Jean","year":"2012","journal-title":"Ophthalmology"},{"key":"2022020214131837100_onco13756-bib-0015","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"2022020214131837100_onco13756-bib-0016","first-page":"140","article-title":"Ipilimumab-induced ocular and orbital inflammation\u2013A case series and review of the literature","volume":"24","author":"Papavasileiou","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"2022020214131837100_onco13756-bib-0017","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJM200009073431015","article-title":"Severe ocular irritation and corneal deposits associated with capecitabine use","volume":"343","author":"Waikhom","year":"2000","journal-title":"N Engl J Med"},{"key":"2022020214131837100_onco13756-bib-0018","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/ICO.0b013e31818fdbc6","article-title":"Persistent corneal epithelial defect associated with erlotinib treatment","volume":"28","author":"Johnson","year":"2009","journal-title":"Cornea"},{"key":"2022020214131837100_onco13756-bib-0019","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2017-08-797886","article-title":"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"2022020214131837100_onco13756-bib-0020","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood-2018-06-858852","article-title":"Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma","volume":"132","author":"Bahlis","year":"2018","journal-title":"Blood"},{"key":"2022020214131837100_onco13756-bib-0021","volume-title":"Karyopharm announces FDA approval of XPOVIO\u00ae (selinexor) as a treatment for patients with multiple myeloma after at least one prior therapy. News release."},{"key":"2022020214131837100_onco13756-bib-0022","volume-title":"Prescribing information","author":"XPOVIO (selinexor) tablets, for oral use","year":"2020"},{"key":"2022020214131837100_onco13756-bib-0023","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/jnci\/87.15.1169","article-title":"Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines","volume":"87","author":"Gianni","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"2022020214131837100_onco13756-bib-0024","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/jnci\/86.14.1099","article-title":"Optic nerve disturbances: A new form of paclitaxel neurotoxicity","volume":"86","author":"Capri","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"2022020214131837100_onco13756-bib-0025","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.jcjo.2019.09.004","article-title":"Carboplatin- and\/or paclitaxel-induced ischemic retinopathy","volume":"55","author":"Elhusseiny","year":"2020","journal-title":"Can J Ophthalmol"},{"key":"2022020214131837100_onco13756-bib-0026","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/oxfordjournals.annonc.a058497","article-title":"Ophthalmic toxicity during carboplatin therapy","volume":"4","author":"Rankin","year":"1993","journal-title":"Ann Oncol"},{"key":"2022020214131837100_onco13756-bib-0027","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamaophthalmol.2018.1851","article-title":"Birdshot-like chorioretinopathy associated with pembrolizumab treatment","volume":"136","author":"Acaba-Berrocal","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"suppl 15","key":"2022020214131837100_onco13756-bib-0028","doi-asserted-by":"crossref","first-page":"8011a","DOI":"10.1200\/jco.2015.33.15_suppl.8011","article-title":"Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D","volume":"33","author":"Patnaik","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022020214131837100_onco13756-bib-0029","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/1346-8138.13612","article-title":"Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient","volume":"44","author":"Arai","year":"2017","journal-title":"J Dermatol"},{"key":"2022020214131837100_onco13756-bib-0030","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13756","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13756","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/7\/619\/42367303\/oncolo_26_7_619.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/7\/619\/42367303\/oncolo_26_7_619.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T14:13:54Z","timestamp":1643811234000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/7\/619\/6510468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,8]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4,8]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13756","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,4,8]]}}}